DALLAS and FORT WORTH, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a
pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its
proprietary modified-release drug delivery technologies, today announced that it will report first quarter 2018 financial results
prior to the opening of U.S. financial markets on Wednesday, May 9, 2018. Neos management will host a conference call and live
audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for
international callers, and referencing conference ID number 1988619. A live audio webcast for the conference call will be available
on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and
commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT®
(amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT®
(methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys ER™ (amphetamine)
extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the
first three approved products using the Company’s extended-release technology platform. Additional information about Neos is
available at www.neostx.com.
Contacts:
|
Richard Eisenstadt
Chief Financial Officer
Neos Therapeutics
(972) 408-1389
reisenstadt@neostx.com
|
|
Sarah McCabe
Senior Vice President
Stern Investor Relations, Inc.
(212) 362-1200
sarah@sternir.com
|
|
|
|
![Primary Logo](https://resource.globenewswire.com/Resource/Download/f2ff2f0a-adaf-45b6-8260-69343b572ad1?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=NzA2MzkjNzIyODM4Ng==)